Evidence map›Paper›PMID 35449812›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

The Combination of Zerumbone with 5-Fluorouracil for Sensitizing Colorectal Cancer-Associated Fibroblasts to Treatment.

Sima Nobari, Rezvan Najafi, Ali Mahdavinezhad, Akram Jalali, Razieh Amini

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sima NobariResearch Center for Molecular Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0003-4004-5177
Rezvan NajafiResearch Center for Molecular Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0003-1326-1288
Ali MahdavinezhadResearch Center for Molecular Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0002-1314-8229
Akram JalaliResearch Center for Molecular Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0002-1606-7854
Razieh AminiResearch Center for Molecular Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0002-7588-3552
Hamedan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to evaluate the synergic effects of combination therapy on 5-fluorouracil (5-FU) resistance-cancer-associated fibroblasts (CAFs) to treatment. Chemotherapy resistance is an important challenge in colorectal cancer (CRC) eradication attention to the tumor microenvironment (TME) is very important. CAFs in the TME play an essential role in cancer chemoresistance and relapse. Additionally, many patients with advanced CRC show resistance to 5-FU therapy. Anti-tumorigenic activities of ZER, a chemopreventive compound derived from the rhizomes of the wild ginger, have been demonstrated. Synergistic and potentiating effects of combination therapy, using herbal and chemical drugs, can improve patients' response. At the first, CAFs were isolated from a CRC patient and sorted by fluorescent-activated cell sorting (FACS), then, confirmed by flow cytometry, and immunocytochemistry (ICC). The effect of 5-FU and ZER on the cell viability was investigated by MTT assay in a dose and time-dependent manner, after that, the expression of vimentin,

Identifiers

PMID35449812
PMCPMC9017496
OpenAlexW4223590297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.